AstraZeneca Strengthens Diabetes R&D With Option On Prosidion's Early-Stage Compounds
This article was originally published in The Pink Sheet Daily
AstraZeneca has entered into an option agreement on Prosidion's first-in-class GPR119 receptor agonists for diabetes.
You may also be interested in...
Biosimilars took center stage during the last two weeks of 2011, as Amgen and Watson and then Baxter and Momenta followed up on the collaboration between Biogen Idec and Samsung BioLogics earlier in the month.
Olaparib and TC-5214 development setbacks at AstraZeneca lead to $380 million charge in the fourth quarter, with core EPS likely at the bottom of the expected range.
The big pharma beats analysts' estimates for the third quarter, but all eyes are turned toward its pipeline as the Plavix patent expiry becomes a near-term reality.